Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Infect Chemother ; 26(2): 205-210, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31537472

RESUMEN

Hepatitis C virus (HCV) infection affects an estimated 71 million people worldwide. HCV is classified into eight genotypes and >70 subtypes. Determination of HCV genotype is important for selection of type and duration of antiviral therapy, and genotype is also a predictor of treatment response. The most commonly used HCV genotyping method in clinical laboratories is a hybridization-based line probe assay (LiPA; Versant HCV Genotype 2.0). However, these methods have a lack of specificity in genotype identification and subtype assignment. Here, we compared the performance of Versant HCV Genotype 2.0 with the gold standard direct sequencing of the NS5B region, in 97 samples from Mexican patients. We found a genotypic concordance of 63.9% between these methods. While 68 samples (70%) were classified into HCV genotype 1 (GT1) by NS5B sequencing, it was not true for 17 samples (17.5%), which were not match HCV subtype by LiPA. Furthermore, nine of the 33 samples classified by NS5B sequencing as GT1a were not identified by LiPA. Use of direct sequencing could improve selection of the optimal therapy, avoid possible failures of therapy and avoid high costs resulting from incorrect genotyping tests in settings without broad access to pangenotypic regimens.


Asunto(s)
Técnicas de Genotipaje/métodos , Hepacivirus/genética , Hepatitis C/virología , ARN Viral , Análisis de Secuencia de ARN/métodos , Proteínas no Estructurales Virales/genética , Estudios Transversales , Humanos , México
2.
J Med Virol ; 90(7): 1277-1282, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29508903

RESUMEN

The HCV 5'UTR, Core/E1, and NS5B regions of samples from fifty patients infected with the hepatitis C virus (HCV) were analyzed. Seventeen patients were identified with genotype (GT) 1b, eleven with GT-1a, nine with GT-2b and four with GT-3a. Two rare subtypes were detected: GT-2j in two patients and GT-2r in one patient. Three patients had mixed infections: one with GT-2k + 2j and two with GT-1b + 2b. This work identifies HCV GTs, 2j, 2k, and 2r for the first time in Mexico.


Asunto(s)
Variación Genética , Genotipo , Hepacivirus/clasificación , Hepacivirus/genética , Hepatitis C/virología , Regiones no Traducidas 5'/genética , Adulto , Ciudades , Femenino , Técnicas de Genotipaje , Hepacivirus/aislamiento & purificación , Humanos , Masculino , México , Persona de Mediana Edad , Análisis de Secuencia de ADN , Proteínas del Núcleo Viral/genética , Proteínas del Envoltorio Viral/genética , Proteínas no Estructurales Virales/genética
3.
J Infect Chemother ; 24(11): 928-931, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29773440

RESUMEN

Hepatitis C virus (HCV) infection is a global health problem. HCV has been classified into seven genotypes and >67 subtypes. Genotyping is necessary to enable selection of appropriate treatments. The commercial molecular techniques currently used do not identify some HCV subtypes, mixed infections and recombinant forms. In this study, the core-E1 and NS5B regions were sequenced and phylogenetically analysed to identify infections by HCV recombinant genotype 1b-2b in two patients who had initially been diagnosed with HCV genotype 2 infection by reverse hybridization with a Versant HCV Genotype 2.0 Assay. Response to treatment was monitored by viral kinetics. Therapeutic failure occurred with initial treatment with PEGylated interferon-α2b and ribavirin, but the use of sofosbuvir and daclatasvir on a re-treatment regimen after reclassification of the infecting virus resulted in a sustained virologic response. The use of a sequencing approach in treatment-naïve infected patients could enable physicians to select the optimal therapy and avoid possible relapses and adverse reactions associated with antiviral therapy.


Asunto(s)
Antivirales/uso terapéutico , Hepacivirus/genética , Hepatitis C/tratamiento farmacológico , Imidazoles/uso terapéutico , Sofosbuvir/uso terapéutico , Adulto , Carbamatos , Quimioterapia Combinada/métodos , Femenino , Técnicas de Genotipaje , Hepacivirus/aislamiento & purificación , Hepatitis C/virología , Humanos , Masculino , Persona de Mediana Edad , Pirrolidinas , ARN Viral/aislamiento & purificación , Retratamiento/métodos , Análisis de Secuencia de ARN , Respuesta Virológica Sostenida , Insuficiencia del Tratamiento , Valina/análogos & derivados , Proteínas no Estructurales Virales/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA